In a study of adults who were new to HIV-1 treatment, the percentage of those who had an undetectable viral load at week 96 were:
77% when taking DELSTRIGO
74% when taking Atripla
(another HIV-1 medicine)
DELSTRIGO may not have these effects in all patients.
HOW IT WAS STUDIED
The safety and efficacy of DELSTRIGO was compared to Atripla over 96 weeks in adults who were new to HIV-1 treatment.
364 adults took DELSTRIGO
364 adults took Atripla
Patients were assigned by chance to take one of the two treatment regimens, and neither the patient nor the healthcare providers taking part in the study knew which regimen they were taking.